ReviewIndian journal of endocrinology and metabolism
Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis.
Review in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Cholesterol Overload Drives Hepatic Steatosis by Inhibiting OGT-dependent PPARα O-GlcNAcylation and Transactivation.International journal of biological sciences · 2026Article
- Fibrates : Do They Still Have a Role in Therapy in 2025?Current atherosclerosis reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fenofibrate forms the standard of care for managing hypertriglyceridemia. Many of these patients have associated metabolic dysfunction-associated steatotic liver disease (MASLD). No systematic review and meta-analysis (SRM) has analysed the impact of fenofibrate in MASLD. Hence, we undertook this SRM. Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving MASLD patients receiving fenofibrate as an intervention and placebo/active comparator as control. The primary outcome was changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Secondary outcomes were alterations in liver fat (ultrasonography or magnetic resonance imaging), lipid parameters, and adverse events. Results: From initially screened 395 articles, data from 5 RCTs were analysed. Fenofibrate had comparable changes in ALT (mean difference [MD]-0.32 IU/L [95% confidence interval [CI]: -6.70-7.33]; Conclusion: This SRM provides us with reassuring safety data on use of fenofibrate in MASLD. Fenofibrate is largely MASLD neutral and continues to have good triglyceride lowering properties in MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.